Edwards Lifesciences Is Maintained at Buy by Citigroup
Edwards Lifesciences Is Maintained at Buy by
Edwards Lifesciences Price Target Raised to $106.00/Share From $105.00 by Citigroup
Edwards Lifesciences Price Target Raised to $106.00/Share From $105.00 by
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $106
Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $105 to $106.
Edwards Lifesciences(EW.US) Officer Sells US$466.47K in Common Stock
$Edwards Lifesciences(EW.US)$ Officer BOBO DONALD E JR sold 5,000 shares of common stock on Jul 10, 2024 at an average price of $93.2948 for a total value of $466.47K.Source: Announcement What is
Edwards Lifesciences Welcomes Dr. Feinberg to Board
CNBC Halftime Report Final Trades: Edwards Lifesciences, IShares Dow Jones US Real Estate ETF, First Citizens Bank, UnitedHealth
CNBC Halftime Report Final Trades: Edwards Lifesciences, IShares Dow Jones US Real Estate ETF, First Citizens Bank,
Citigroup Adjusts Price Target on Edwards Lifesciences to $106 From $105
Edwards Lifesciences (EW) has an average rating of outperform and price targets ranging from $70 to $107, according to analysts by Capital IQ.Price: 92.90, Change: -0.58, Percent Change: -0.62
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $106
Citi analyst Joanne Wuensch maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and adjusts the target price from $105 to $106.According to TipRanks data, the analyst has a success rate of 61.4
Express News | Edwards Lifesciences Corp : Citigroup Raises Target Price to $106 From $105
Unusual Options Activity: TEVA, MAT and Others Attract Market Bets, TEVA V/OI Ratio Reaches 347.7
EST Jul 9th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
PROPEL Fund Deploys $25 Million to Promote Health, Equity and Economic Growth in Underserved Communities
CHICAGO--(BUSINESS WIRE)--Broadstreet Impact Services announced today that it has fully deployed the $25 million PROPEL Fund to finance economic development projects that promote health, wealth and op
$1000 Invested In This Stock 20 Years Ago Would Be Worth $33,000 Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 10.86% on an annualized basis producing an average annual return of 19.18%. Currently, Edwards Lifesciences has a m
A Look Into Edwards Lifesciences' (NYSE:EW) Impressive Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in con
AM Best Assigns Performance Assessment to Edward William Insurance Services LLC
AMSTERDAM--(BUSINESS WIRE)--#insurance--AM Best has assigned a Performance Assessment (assessment) of PA-4 (Fair) to Edward William Insurance Services LLC (EW) (United States). The outlook assigned to
The Analyst Landscape: 13 Takes On Edwards Lifesciences
13 analysts have expressed a variety of opinions on Edwards Lifesciences (NYSE:EW) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table encapsulates th
Edwards Lifesciences Is Maintained at In-Line by Evercore ISI Group
Edwards Lifesciences Is Maintained at In-Line by Evercore ISI Group
Edwards Lifesciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 1.51% Evercore ISI Group $89 → $91 Maintains In-Line 05/30/2024 19.35% Goldman Sachs → $107 Ini
Evercore Maintains Edwards Lifesciences(EW.US) With Hold Rating, Raises Target Price to $91
Evercore analyst Vijay Kumar maintains $Edwards Lifesciences(EW.US)$ with a hold rating, and adjusts the target price from $89 to $91.According to TipRanks data, the analyst has a success rate of 47.4
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating
Edwards Lifesciences (EW) has an average outperform rating and a price target range of $70 to $107, according to analysts polled by Capital IQ. Price: 91.00, Change: +0.75, Percent Change: +0.83
Deutsche Numis Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $103
Deutsche Numis analyst Pito Chickering maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $103.According to TipRanks data, the analyst has a success rate of 5